

PROGRAM 20 April

SESSION IV

Chairs: Lesley-Ann Sutton & Anders Österborg

08.30 - 09.00

C.I. Edvard Smith: The History of Bruton's Tyrosine Kinase

09.00 - 09.40

Richard Rosenquist Brandell & Davide Rossi: How to identify high-risk patients?

09.40 - 10.20

Peter Hillmen: How to treat high-risk patients

10.20 - 10.30

Discussion

10.30 - 11.00

Coffee

SESSION V

Chairs: Jeanette Lundin & Vesa Lindström

11.00 - 11.40

Workshop: Presentation of Nordic Guidelines on Diagnostics and Treatment

Maria Strandberg, Sweden

Hoa Tran, Norway

Ilse Christiansen, Denmark

Vesa Lindström, Finland

11.40 - 12.30

Discussion of discrepancies and similarities between guidelines

Peter Hillmen, Michael Hallek & Paolo Ghia are facilitating the discussion

- Prognostic / predictive time and which ones, newer prognostics like recurrent mutations for routine analyses
- First line treatment options
- Later line treatment options
- Indefinite vs defined length of treatment
- How to treat elderly and frail

12.30 - 13.30

Lunch

SESSION VI

Chairs: Caspar da Cunha-Bang & Lotta Hansson

13.30 - 14.20

Real real-world / Registry-based studies

Lotta Hansson, Caspar da Cunha-Bang, Andrea Lenartova & Vesa Lindström

14.20 - 14.45

Nordic CLL Group: planned and future activities

(discussion led by Carsten Niemann & Anders Österborg)

14.45 - 15.30

Michael Hallek: The future of therapy of chronic lymphocytic leukemia

15.30

Meeting ends